Apellis On Saturday Provided Update On Review Of Rare Safety Events With Syfovre For Geographic Atrophy; Said No Indication That Drug Product Or Manufacturing Issues Contributed To Rare Events Of Retinal Vasculitis
Portfolio Pulse from Charles Gross
Apellis Pharmaceuticals provided an update on its review of rare events of retinal vasculitis reported in real-world treatment with SYFOVRE for geographic atrophy. The company confirmed seven total events since launch, with more than 68,000 SYFOVRE vials distributed to date. There was no indication that drug product or manufacturing issues contributed to these events.
July 30, 2023 | 1:38 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Apellis Pharmaceuticals' update on SYFOVRE's rare events of retinal vasculitis may raise concerns among investors, potentially impacting the stock negatively in the short term.
The news about the rare events of retinal vasculitis associated with Apellis' SYFOVRE could raise safety concerns among patients and healthcare providers, potentially affecting the drug's sales and the company's revenues. This could negatively impact the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100